Prevalence of sexually transmitted infections in HIV-1 infected pregnant women in Europe
First Online: 10 October 2007 Received: 20 March 2007 Accepted: 18 September 2007 DOI:
10.1007/s10654-007-9188-0 Cite this article as: Landes, M., Thorne, C., Barlow, P. et al. Eur J Epidemiol (2007) 22: 925. doi:10.1007/s10654-007-9188-0 Abstract
We investigated prevalence of sexually transmitted infections (STI) in a cohort of HIV-1-infected pregnant women and described factors associated with STI diagnosis, as a nested study within the European Collaborative Study (ECS). The ECS is a cohort study in which HIV-infected pregnant women are enrolled and their children followed from birth, according to standard clinical and laboratory protocols. Information on STIs diagnosed during pregnancy was collected retrospectively from the antenatal records of women enrolling between January 1999 and October 2005; other variables were obtained from the ECS prospective database. A total of 1,050 women were included: 530 in Western Europe and 520 in Ukraine. Syphilis was the most common bacterial STI (2% prevalence, 95% CI 1.2–3.0). Prevalence of HPV-related genital lesions was 8.6% (95%CI 6.9–10.4) and prevalence of
Trichomonas vaginalis was 12.1% (95%CI 10.2–14.2). Women in Ukraine (AOR 10.7, 95%CI 3.7–30.5), single women (AOR 3.9, 95%CI 1.2–12.7), sexual partners of injecting drug users (AOR 3.8, 95%CI 1.4–10.4) and women with CD4 counts <200 cells/mm 3 (AOR 5.4, 95%CI 1.0–28.1) were at increased risk of diagnosis with Chlamydia trachomatis, syphilis or Trichomonas vaginalis. African origin (AOR 1.9, 95%CI 1.1–3.3) and CD4 count <200 cells/mm 3 (AOR 3.4, 95%CI 1.5–7.8) were associated with HSV-2 and/or HPV-related genital lesions. Antenatal screening should be considered an effective tool for diagnosis, treatment and prevention of further transmission of STIs. HIV-infected women should receive adequate screening for STIs during pregnancy together with appropriate counseling and follow-up for treatment and prevention. Keywords Antenatal Human immunodeficiency virus Prevalence Risk factors Sexually transmitted infection Abbreviations CDC
Centers for Disease Control and Prevention
European Collaborative Study
Highly active antiretroviral therapy
Human immunodeficiency virus
Herpes simplex virus 2
Injecting drug use
Sexually transmitted infections
Electronic Supplementary Material
The online version of this article (doi:
) contains supplementary material, which is available to authorized users. 10.1007/s10654-007-9188-0 References
EuroHIV (European Centre for the Epidemiological Monitoring of AIDS). HIV/AIDS surveillance in Europe, mid-year report 2005. 72. 2006. Paris: EuroHIV.
UNAIDS (2006) Report on the global AIDS epidemic, 2006. Geneva: UNAIDS.
D’Arminio MA, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005;165:416–23.
Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005;366:378–84.
European Collaborative Study: The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS 2006;20:1419–27.
UNAIDS. The changing HIV/AIDS epidemic in Europe and Central Asia. 2004. Geneva, UNAIDS.
. Accessed 1 Mar 2007.
Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992;19:61–77.
Cohen MS. HIV and sexually transmitted diseases: lethal synergy. Top HIV Med 2004;12:104–7.
McClelland RS, Lavreys L, Katingima C, et al. Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis 2005;191:333–8.
Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001;28:579–97.
Radcliffe KW, Ahmad S, Gilleran G, Ross JD. Demographic and behavioural profile of adults infected with
: a case-control study. Sex Transm Infect 2001;77:265–70.
Mavrov GI, Bondarenko GM. The evolution of sexually transmitted infections in the Ukraine. Sex Transm Infect 2002;78:219–21.
Brown AE, Sadler KE, Tomkins SE, et al. Recent trends in HIV and other STIs in the United Kingdom: data to the end of 2002. Sex Transm Infect 2004;80:159–66.
Leszczynska-Gorzelak B, rmochwal-Kolarz D, Borowiec-Blinowska A, Oleszczuk J: The prevalence of
infection in pregnant women. Med Wieku Rozwoj 2005;9:27–35.
Ickovics JR, Niccolai LM, Lewis JB, Kershaw TS, Ethier KA: High postpartum rates of sexually transmitted infections among teens: pregnancy as a window of opportunity for prevention. Sex Transm Infect 2003;79:469–73.
van Benthem BH, Prins M, Larsen C, Delmas MC, Brunet JB, van den HA. Sexually transmitted infections in European HIV-infected women: incidence in relation to time from infection. European Study on the Natural History of HIV Infection in Women. AIDS 2000;14:595–603.
Magnus M, Clark R, Myers L, Farley T, Kissinger PJ.
among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent
positivity? Sex Transm Dis 2003;30:839–43.
European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458–65.
Centers For Disease Control and Prevention. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR 1998;47:1–116.
Centers For Disease Control and Prevention. Guidelines for the treatment of sexually transmitted diseases - 2002. MMWR 2002;51:1–78.
Mbopi-Keou FX, Gresenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000;182:1090–6.
World Health Organisation Regional Office for Europe. Centralized Information Service for Infectious Disease. 2006.
http://data.euro.who.int/cisid/?TabID = 48830
. Accessed 1 Mar 2007.
Rhodes T, Simic M. Transition and the HIV risk environment. BMJ 2005;331:220–3.
Celum C, Levine R, Weaver M, Wald A. Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ 2004;82:447–53.
Greenblatt RM, Lukehart SA, Plummer FA et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 1988;2:47–50.
Weiss HA, Buve A, Robinson NJ et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS 2001;15 Suppl 4:S97–108.
Freeman EE, Glynn JR. Factors affecting HIV concordancy in married couples in four African cities. AIDS 2004;18:1715–21.
Greenblatt RM, Bacchetti P, Barkan S, et al. Lower genital tract infections among HIV-infected and high-risk uninfected women: findings of the Women’s Interagency HIV Study (WIHS). Sex Transm Dis 1999;26:143–51.
Palefsky JM, Minkoff H, Kalish LA et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999;91:226–36.
Chen KT, Segu M, Lumey LH, et al. Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstet Gynecol 2005;106:1341–8.
Wilson TE, Minkoff H, McCalla S, Petterkin C, Jaccard J: The relationship between pregnancy and sexual risk taking. Am J Obstet Gynecol 1996;174:1033–6.
Niccolai LM, Ethier KA, Kershaw TS, Lewis JB, Ickovics JR. Pregnant adolescents at risk: sexual behaviors and sexually transmitted disease prevalence. Am J Obstet Gynecol 2003;188:63–70.
Fiore S. HIV infected women in Europe. PhD thesis. University of London; 2005.
Sorvillo F, Kovacs A, Kerndt P, Stek A, Muderspach L, Sanchez-Keeland L. Risk factors for trichomoniasis among women with human immunodeficiency virus (HIV) infection at a public clinic in Los Angeles County, California: implications for HIV prevention. Am J Trop Med Hyg 1998;58:495–500.
Rosengard C, Anderson B, Stein MD. Intravenous drug users’ HIV-risk behaviors with primary/other partners. Am J Drug Alcohol Abuse 2004;30:225–36.
Silverberg MJ, Ahdieh L, Munoz A, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002;29:427–35.
Fennema JS, van Ameijden EJ, Coutinho RA, van den Hoek AA. HIV, sexually transmitted diseases and gynaecologic disorders in women: increased risk for genital herpes and warts among HIV-infected prostitutes in Amsterdam. AIDS 1995;9:1071–8.
Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004;35:435–45.
Strickler HD, Burk RD, Fazzari M et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005;97:577–86.
Dunn EF, Markowitz LE. Genital human papillomavirus infection. Clin Inf Dis 2006;43: 624–9.
CrossRef Copyright information
© Springer Science+Business Media B.V. 2007